Ubiquiti Inc. logo

Ubiquiti Inc. (UI)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
577. 92
+9.44
+1.66%
$
35.28B Market Cap
20.49 P/E Ratio
2.4% Div Yield
79,327 Volume
6.87 Eps
$ 568.48
Previous Close
Day Range
561 579.71
Year Range
255 803.6
Want to track UI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 59 days
Take the Zacks Approach to Beat the Markets: Ubiquiti, Flotek Industries & Goldman Sachs in Focus

Take the Zacks Approach to Beat the Markets: Ubiquiti, Flotek Industries & Goldman Sachs in Focus

Ubiquiti, Flotek and Goldman Sachs stand out as top Zacks picks, each posting major gains after key rating upgrades.

Zacks | 5 months ago
Down 5.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Ubiquiti (UI)

Down 5.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Ubiquiti (UI)

The heavy selling pressure might have exhausted for Ubiquiti (UI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks | 5 months ago
Ubiquiti Q3 Earnings Beat Estimates, Top Line Surges Y/Y

Ubiquiti Q3 Earnings Beat Estimates, Top Line Surges Y/Y

UI reports top-line growth year over year in fiscal Q3, backed by healthy demand in the Enterprise Technology segment products across several regions.

Zacks | 6 months ago
Ubiquiti Inc. (UI) Beats Q3 Earnings and Revenue Estimates

Ubiquiti Inc. (UI) Beats Q3 Earnings and Revenue Estimates

Ubiquiti Inc. (UI) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.28 per share a year ago.

Zacks | 7 months ago
Ubiquiti Skyrockets 184% in a Year: Worth Betting on UI Stock Now?

Ubiquiti Skyrockets 184% in a Year: Worth Betting on UI Stock Now?

With healthy fundamentals and solid price appreciation, UI appears to be an enticing investment option in the volatile market.

Zacks | 9 months ago
Ubiquiti Q2 Earnings Beat Estimates, Top Line Surges Y/Y

Ubiquiti Q2 Earnings Beat Estimates, Top Line Surges Y/Y

UI reports top-line growth year over year in the second quarter of fiscal 2025, owing to healthy demand in several end markets.

Zacks | 10 months ago
Ubiquiti Inc. (UI) Tops Q2 Earnings and Revenue Estimates

Ubiquiti Inc. (UI) Tops Q2 Earnings and Revenue Estimates

Ubiquiti Inc. (UI) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.38 per share a year ago.

Zacks | 10 months ago
Ubiquiti (UI) Upgraded to Strong Buy: Here's What You Should Know

Ubiquiti (UI) Upgraded to Strong Buy: Here's What You Should Know

Ubiquiti (UI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 10 months ago
UI Surges 215% in the Past Year: Should You Bet on the Stock Now?

UI Surges 215% in the Past Year: Should You Bet on the Stock Now?

With healthy fundamentals, UI more than doubled in the past year, making it a solid investment option at the moment.

Zacks | 10 months ago
Ubiquiti (UI) Soars 8.6%: Is Further Upside Left in the Stock?

Ubiquiti (UI) Soars 8.6%: Is Further Upside Left in the Stock?

Ubiquiti (UI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks | 10 months ago
UI Stock Appears a Solid Investment Bet Now: Here's Why

UI Stock Appears a Solid Investment Bet Now: Here's Why

With healthy fundamentals and a unique business model, UI appears to be a solid investment option at the moment.

Zacks | 11 months ago
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics' breakout and Cardiff Oncology's promising trial data present compelling buy opportunities, while Advantest Corporation's high valuation suggests caution.

Seekingalpha | 11 months ago
Loading...
Load More